Clinical Trial Supply Chains Face New Challenges from Tariffs and AI Disruption
核心洞察
Industry experts at the 2025 Clinical Trial Supply West Coast conference identified risk management as critical for pharmaceutical supply chains amid rising tariffs and AI disruption.
President Trump's tariffs on pharmaceutical imports, including a 15% rate on EU products with potential increases to 250%, are forcing companies to develop backup sourcing strategies.
Artificial intelligence is accelerating the shift from site-centric to patient-centric clinical trials, though human input remains essential for interventional trials with scarce data.
The pharmaceutical industry is grappling with unprecedented supply chain challenges as new tariffs, artificial intelligence disruption, and regulatory shifts force companies to fundamentally rethink their risk management strategies. These concerns dominated discussions at the opening session of the 2025 Clinical Trial Supply West Coast conference in Burlingame, California, where industry leaders outlined the evolving landscape facing clinical trial operations.
Tariff Impact Reshapes Supply Strategy
President Trump's newly imposed tariffs on pharmaceutical imports are creating significant uncertainty for clinical trial supply chains. A 15% tariff rate has been established for imports from the European Union, with Trump indicating rates could potentially reach as high as 250%. These trade policies are driving companies to develop more sophisticated backup plans and dual sourcing strategies for critical materials.
"It seems that the unforeseen circumstances are getting bigger and more frequent: pandemic, some geopolitical instability, natural disaster, regulatory shifts," stated Paul Hingst, supply chain consultant at Crinetics Pharmaceuticals, who moderated the conference panel.
Dr. Prasun Mishra, founding director of Agility Pharmaceuticals (搜索), noted that new trade regulations are fueling growth of manufacturing hubs in the United States. However, he emphasized that regions like China and India retain competitive advantages through robust infrastructure, low costs, and manufacturing speed.
Naymisha Patel, senior vice president at Tenaya Therapeutics, advised that developers can best navigate tariffs by stockpiling critical materials while considering alternative therapies if supply chains are threatened. She highlighted that investors now demand greater insight into regulatory compliance and quality assurance factors to better secure returns.
AI Transformation and Limitations
Artificial intelligence is beginning to demonstrate cost-saving benefits in clinical trials, according to conference panelists. The technology is accelerating the transition from site-centric to patient-centric clinical trials, fundamentally changing how studies are conducted and managed.
However, Patel identified significant limitations in AI applications for interventional trials, where data are often scarce and fragmented. In these scenarios, human input remains essential for effective trial management and decision-making.
Regulatory Landscape in Flux
Several regulatory changes are positioned to impact the clinical trials sector significantly. The FDA finalized guidance on decentralized trials in September 2024, supporting the industry's shift toward patient-centric approaches that Mishra described.
The regulatory environment has also seen some uncertainty regarding diversity requirements. The FDA had previously drafted a Diversity Action Plan requiring sponsors to develop strategies for enrolling underrepresented groups, with finalization expected by June 2025. However, Patel noted these materials were removed from the FDA's website in early 2025. Robert F. Kennedy Jr., upon his nomination as secretary of health and human services, committed to finalizing the diversity guidance, though no firm timeline has emerged.
Investment Climate Shifts
The post-pandemic funding landscape has created additional challenges for drug developers. While the Covid-19 pandemic brought an influx of funding to the clinical sector, a subsequent decline means developers must now demonstrate not only their drugs' efficacy but also post-marketing potential, as investors have become increasingly risk-averse.
This shift in investor sentiment is driving companies to maintain more comprehensive backup plans, including dual sourcing of critical materials and enhanced coordination on drug transport to mitigate risks associated with global transport routes.
Industry Response and Adaptation
The clinical trials industry is adapting to these multiple pressures through enhanced risk management strategies and supply chain diversification. Companies are being forced to balance cost considerations with supply security, often requiring more complex logistics and planning processes.
The convergence of tariff pressures, technological disruption, and regulatory changes is creating a new operating environment where traditional supply chain models may no longer be sufficient. Industry leaders emphasize that success will depend on companies' ability to build flexibility and resilience into their operations while maintaining the quality and compliance standards essential for clinical trial success.